logo
Byredo Owner Puig to Weigh Share Buyback in Time, CEO Says

Byredo Owner Puig to Weigh Share Buyback in Time, CEO Says

The billionaire family controlling Puig Brands SA may weigh options — including buying its stock — to revive the Spanish beauty-products group's sagging shares, its chief executive officer said.
Shares of Puig, owner of perfume brands like Jean Paul Gaultier and makeup label Charlotte Tilbury, had tumbled more than 34 percent since its splashy listing as Europe's biggest IPO in 2024. In early Madrid trading on Monday, they rose as much as 2 percent.
'Over time we'll consider whether or not it makes sense to make any moves to help investors who have invested in the stock achieve the value they believe it deserves,' Marc Puig said in an interview, referring to a possible family led stock purchase or ways to increase the liquidity of its shares. 'No moves are planned in the short term.'
The Puigs are among Europe's wealthiest families. They own Exea Empresarial, which controls 74 percent of Puig's capital and 93 percent of its voting rights.
Puig shares have tumbled like those of others in the industry including L'Oréal SA and LVMH as they suffer from uncertainty over the effects of US President Donald Trump's tariff wars and concerns about sluggish consumer demand. For Puig, the decline has come even though it has consistently met targets.
'I don't feel like we've let anyone down,' Puig said. 'We've delivered, we continue to grow.'
Most analysts have a 'buy' recommendation on the stock. 'So far everything they've promised has happened,' said Xavier Brun, Head of Equity at Trea Asset Management, which holds Puig shares.
On Wednesday, the company reiterated its forecast of 6 to 8 percent organic sales growth for the year, even after factoring in a 20 percent US tariff on Europe-made products. Trump has threatened 30 percent tariffs on products from the European Union. Puig said it expected little impact from the trade war in 2025 since most of the products are already in the US.
Analysts like Patrick Folan at Barclays said the company has been less forthcoming about the outlook beyond this year.
'It would be helpful for Puig to come to market and explain what the current moderation in category growth means for them, and clearly state why they could be ok compared to the wider market,' he said. 'It's important to evolve the messaging from the IPO, as the IPO expectations of market growth may no longer be realistic next year or in 2027.'
Puig plans to provide guidance for next year once he has more clarity on subjects like tariffs and the dollar.
'It'll be good to clarify these doubts to better measure consumer sentiment,' he said.
For now, the executive, who's been at the helm for more than two decades, says the company's going to stick to doing what it does best — creating and selling fragrances. It will also focus on its make-up and skincare products, whose growth stood out in the most recent quarter even as fragrance sales moderated.
That strategy of hunkering down and focusing on it core business has paid off for the company in the past. In the early 2000s, when Marc Puig took charge, the company faced financial difficulties and restructured the business to cut costs and allocate more resources toward building its perfume brands. Years later, that turnaround allowed it to stretch its fragrance portfolio.
Puig now holds three spots in the world's top ten fragrance label rankings after Jean Paul Gaultier, its fastest growing brand, entered the list last year.
Puig's focus on its prestige perfumes portfolio, which accounts about 70 percent of sales, and pipeline of products should sustain expansion and deliver better growth than its premium-beauty peers, Bloomberg Intelligence analysts Andrea Ferdinando Leggieri and Deborah Aitken wrote in a report on July 7.
For Puig, much of the work of concocting new perfumes happens inside the glass-walled chamber high up in its new tower in Barcelona, which was inaugurated by King Felipe VI and Queen Letizia of Spain last year.
Here, Gregorio Sola, a master perfumer, waxes lyrical about his trips around the world to find the finest ingredients: sandalwood oil from trees that have to grow for 30 to 40 years or a rare, signature rose.
Fragrances inspired by the bold smells of the 1980s and 90s are making a comeback, Sola says. The growth of the market is being fuelled by young consumers' appetite for unique and expressive fragrances. Puig tapped that market early when it started acquiring niche brands like L'Artisan Perfumeur and Byredo, which often have unconventional compositions and limited distribution.
Beginning over a century ago as a distributor of French perfumes, Puig made a major shift in the early 20th century to manufacture its own products like Spain's first homegrown lipstick. In the 60s and 70s, it began partnering with fashion designers like Paco Rabanne to launch fragrances — doubling down later by acquiring entire fashion houses like Carolina Herrera and Nina Ricci.
'What we need to do is take risks, tell good stories, and make exceptional products,' he said. 'I'd like to think we're able to continue getting people excited about our products.'
By Rodrigo Orihuela and Clara Hernanz Lizarraga
Learn more:
Byredo, Paco Rabanne Owner Puig Sales Rise 8%
The Spanish beauty conglomerate saw growth in all three of its divisions, which include the Dr. Barbara Sturm, Charlotte Tilbury and Carolina Herrera brands.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ATARI: Capital increase in relation to the repayment in shares of loans from IRATA LLC
ATARI: Capital increase in relation to the repayment in shares of loans from IRATA LLC

Yahoo

time21 minutes ago

  • Yahoo

ATARI: Capital increase in relation to the repayment in shares of loans from IRATA LLC

Capital increase in relation to the repayment in shares of loans from IRATA LLC PARIS, FRANCE (August 7, 2025 - 6.00 pm CET) - Atari® (Euronext Growth Paris: ALATA) — one of the world's most iconic consumer brands and interactive entertainment producers — today announces the repayment of€13.9 million loans previously granted to Atari SA by Irata LLC, the holding company of Wade Rosen, Chairman and Chief Executive Officer of Atari SA, through a capital increase reserved to IRATA LLC. The repayment in Atari SA new shares and the reserved capital increase have been approved unanimously by the Board of Directors1 of Atari, SA pursuant to the authorization granted by the shareholders meeting held on September 24, 2024 (Resolution 12). The loans which are repaid, had been granted on January 31, 2024, March 4, 2024, April 10, 2024, July 22,2024, July 31, 2024, January 3, 2025 and January 31, 2025 for a total amount (principal and interest) of €13.9 million and bearing an annual interest of 10%. Upon repayment of the loans, 97,718,187 new shares (representing 21% of Atari, SA share capital) will be issued with no discount on the share price2 and will be admitted to trading. As a result, the total number of outstanding shares will be 559,082,939. Following this capital increase, IRATA LLC will hold 41.7% of the share capital and 39.5% of the voting rights3. After this repayment, the outstanding amount of loans granted by IRATA LLC to Atari, SA and its subsidiaries represent approximately €10M in principal amount. Breakdown of capital, before capital increase Ownership June 30, 2025 Number ofshares % Theoreticalvoting rights % Exercisablevoting rights % Irata LLC 135,379,861 29.3% 135,979,861 27.3% 135,979,861 27.5% Stephen Kick 31,463,004 6.8% 62,926,008 12.6% 62,926,008 12.7% Mr Alexandre Zyngier 3,779,778 0.8% 4,830,807 1.0% 4,830,807 1.0% Treasury shares 3,253,426 0.7% 3,253,426 0.7% 0 0.0% Public 287,488,683 62.3% 290,559,871 58.4% 290,559,871 58.8% Total 461,364,752 100.0% 497,549,973 100.0% 494,296,547 100.0% Breakdown of capital, after capital increase Ownership Post capital increase Number ofshares % Theoreticalvoting rights % Exercisablevoting rights % Irata LLC 233,098,048 41.7% 233,698,048 39.3% 233,698,048 39.5% Stephen Kick 31,463,004 5.6% 62,926,008 10.6% 62,926,008 10.6% Mr Alexandre Zyngier 3,779,778 0.7% 4,830,807 0.8% 4,830,807 0.8% Treasury shares 3,253,426 0.6% 3,253,426 0.5% 0 0.0% Public 287,488,683 51.4% 290,559,871 48.8% 290,559,871 49.1% Total 559,082,939 100.0% 595,268,160 100.0% 592,014,734 100.0% 1 Mr Wade Rosen abstained from participating in the decision of the Board of Directors2 New Atari shares issued on the basis of a 3-day VWAP as of 31 July 2025 of €0.14503 In addition, IRATA LLC holds 195,163,398 convertible bondsAbout ATARI Atari is an interactive entertainment company and an iconic gaming industry brand that transcends generations and audiences. The company is globally recognized for its multi-platform, interactive entertainment and licensed products. Atari owns and/or manages a portfolio of more than 400 unique games and franchises, including world-renowned brands like Asteroids®, Centipede®, Missile Command®, Pong®, and RollerCoaster Tycoon®. Atari has offices in New York and Paris. Visit us online at Atari shares are listed in France on Euronext Growth Paris (ISIN Code FR0010478248, Ticker ALATA) and OTC Pink Current (Ticker PONGF). ©2025 Atari Interactive, Inc. Atari wordmark and logo are trademarks owned by Atari Interactive, Inc. Contacts Atari - Investor RelationsTel +33 1 83 64 61 57 - investisseur@ | Actus finance & communication - Marie Calleux Tel +33 1 53 65 68 68 – atari@ Listing Sponsor - Euroland CorporateTel +33 1 44 70 20 84 - Julia Bridger - jbridger@ DISCLAIMER This press release contains certain non-factual elements, including but not restricted to certain statements concerning its future results and other future events. These statements are based on the current vision and assumptions of Atari's leadership team. They include various known and unknown uncertainties and risks that could result in material differences in relation to the expected results, profitability and events. In addition, Atari, its shareholders and its respective affiliates, directors, executives, advisors and employees have not checked the accuracy of and make no representations or warranties concerning the statistical or forward-looking information contained in this press release that is taken from or derived from third-party sources or industry publications. If applicable, these statistical data and forward-looking information are used in this press release exclusively for information. Attachment ATARI_PR-Loan-repayment_20250807Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Sources reveal the Trump administration's plans for cutting U.S. drug prices
Sources reveal the Trump administration's plans for cutting U.S. drug prices

Fast Company

time22 minutes ago

  • Fast Company

Sources reveal the Trump administration's plans for cutting U.S. drug prices

The Trump administration has been talking to drugmakers about ways to raise prices of medicines in Europe and elsewhere in order to cut drug costs in the United States, according to a White House official and three pharmaceutical industry sources. U.S. officials told drug companies it would support their international negotiations with governments if they adopt 'most favored nation' pricing under which U.S. drug costs match the lower rates offered to other wealthy countries, the White House official said. The U.S. is currently negotiating bilateral trade deals and setting tariff rates on the sector. The Trump administration has asked some companies for ideas on raising prices abroad, two of the sources said, describing multiple meetings over several months aimed at lowering U.S. prices without triggering cuts to research and development spending drugmakers insist would result. The White House official called the effort collaborative, saying both sides were seeking advice from each other. The U.S. pays more for prescription drugs than any other country, often nearly three times as much as other developed nations. President Donald Trump has repeatedly said he wants to narrow this gap to stop Americans from being 'ripped off.' The previously unreported discussions reflect the challenges Trump faces to achieve that goal, and are the backdrop to the letters he sent last week to CEOs of 17 major drugmakers, urging them to cut U.S. prices to match those paid overseas. Unlike in the U.S., where market forces determine drug prices, European governments typically negotiate directly with companies to set prices for their national healthcare systems. Anna Kaltenboeck, a health economist at Verdant Research, said European nations have leverage to drive pricing and are sometimes willing to walk away from purchasing medicines they deem too expensive. Drugmakers generate most of their sales in the U.S. The Pharmaceutical Research and Manufacturers of America — the industry's main lobby group — has always argued that cutting U.S. prices would stifle innovation by lowering R&D spending. PhRMA declined to comment on the private meetings. Kaltenboeck said past studies had shown that drugmakers made enough money in the U.S. to more than fund their entire global R&D spends. 'Prices can come down in the United States without being increased in other countries, and we can still get innovation,' she said. TOP PRIORITY Despite the Trump administration's tariff threats and pressure to move more manufacturing to the U.S., the push to raise European drug prices is its top priority in discussions with industry, according to a senior executive at a European drugmaker, who spoke on condition of anonymity about the confidential meetings. 'This is the key conversation right now with PhRMA and every company getting that message from Pennsylvania Avenue to a point that we are already executing on it,' the executive said, referring to the White House address. The company had already met with European governments on the issue, the executive added. An E.U. Commission spokesperson said it is in regular contact with the pharma industry and pointed to an agreement with the U.S. that should it impose tariffs on pharmaceuticals, they would be capped at 15%. When asked how the administration would support international drug price negotiations, the White House official referred Reuters to Trump's most favored nation executive order from May. That order directed trade officials to pursue trade and legal action against countries keeping drug prices below fair market value. In last week's letters, Trump complained that since the May executive order, most industry proposals had simply shifted blame for high prices or requested policy changes that would result in billions in industry handouts. A second source, a pharmaceutical executive who was not authorized to speak on the matter, said the Trump administration has been continually meeting with representatives of his company and had discussed strategies for raising drug prices internationally. 'There's a big push from the administration to drive up prices outside the U.S.,' the executive said. The executive said the Trump administration had been looking at using trade talks with the UK and EU as leverage, and considered pressuring countries to spend a higher percentage of GDP on new medicines or offering tariff breaks in exchange for higher drug spending. It was understood that the UK deal specifically aims to get the country to ramp up investment in branded medicines over time, the executive said. A spokesperson for the UK government said it would continue to work closely with the U.S. and its own pharmaceutical industry to understand the possible impact of any changes to drug pricing, without commenting on the trade talks. In April, over 30 industry CEOs including those from AstraZeneca, Bayer and Novo Nordisk signed a letter to European Union President Ursula von der Leyen saying Europe needed to rethink its pricing policies. 'It's going to be very difficult for a country that already has the ability to control what it spends to go in the other direction,' Kaltenboeck said, 'and it doesn't make much sense for them politically.'

Helping Beverage Companies Navigate the EUDR: Beverage Industry Environmental Roundtable (BIER) Releases Sector-Specific Interpretation Guide
Helping Beverage Companies Navigate the EUDR: Beverage Industry Environmental Roundtable (BIER) Releases Sector-Specific Interpretation Guide

Associated Press

time23 minutes ago

  • Associated Press

Helping Beverage Companies Navigate the EUDR: Beverage Industry Environmental Roundtable (BIER) Releases Sector-Specific Interpretation Guide

August 7, 2025 /3BL/ - The Beverage Industry Environmental Roundtable (BIER) has released the Beverage Industry EUDR Interpretation Guide, a practical, sector-specific resource designed to help beverage companies understand and meet the requirements of the European Union Deforestation Regulation (EUDR) (EU 2023/1115). Effective June 29, 2023, the EUDR introduced strict due diligence requirements for companies placing cattle, coffee, cocoa, soy, palm oil, rubber, or wood - or products derived from them - on the EU market or exporting them from it. For the beverage industry, this regulation is highly relevant as it covers both raw ingredients (like coffee, cocoa, and palm derivatives) and select wood-based packaging (such as barrels and branded wooden crates). Full compliance for large and medium-sized operators begins December 30, 2025, with Small and Medium-sized Enterprises (SMEs) following by June 30, 2026. The guide is designed for beverage manufacturers, brand owners, and procurement and sustainability teams who need clear, actionable direction on how to implement EUDR compliance across their supply chains. It provides: By providing a beverage-focused lens on a complex regulation, the guide empowers companies to reduce compliance risk, maintain market access, and build robust, future-proof sustainability practices. 'The EUDR presents both a challenge and an opportunity for the beverage sector. Our members needed clear, actionable guidance on how to navigate this complex regulation, and that's exactly what this guide delivers, helping companies meet their obligations while advancing environmental stewardship.' ~ Erica Pann, Executive Director of BIER. The Beverage Industry EUDR Interpretation Guide reinforces BIER's mission to accelerate environmental progress in the beverage sector by turning complex sustainability challenges into actionable solutions. The Beverage Industry EUDR Interpretation Guide is available for download at For more information, please contact: Erica Pann, BIER Executive Director [email protected] About BIERBIER is a technical coalition of leading global beverage companies working together to advance environmental sustainability within the beverage sector. Formed in 2006, BIER is a common voice across the beverage sector, speaking to influence global standards on environmental sustainability aspects most relevant to the sector, affect change both up and down the supply chain, and share best practices that raise the bar for environmental performance of the industry. By doing so, BIER is able to monitor data and trends, engage with key stakeholders, develop best practices, and guide a course of action for the future. BIER members include Anheuser-Busch InBev, Asahi Group Holdings, Bacardi, Brown-Forman, Carlsberg Group, The Coca-Cola Company, Constellation Brands, Diageo, Heineken, Keurig Dr Pepper, LION, Molson Coors, Monster Energy, Ocean Spray Cranberries, PepsiCo, Pernod Ricard and Suntory Global Spirits. For more information, visit Visit 3BL Media to see more multimedia and stories from Beverage Industry Environmental Roundtable

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store